Published online before print June 28, 2004, doi: 10.1161/01.CIR.0000135589.85501.DB
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:259-264.)
© 2004 American Heart Association, Inc.
Original Articles |
Clinical and Economic Outcomes of Percutaneous Coronary Interventions in the Elderly
An Analysis of Medicare Claims Data
From the Department of Health Economics and Outcomes Research, Boston Scientific Corporation, Natick, Mass (M.A.C., M.L., E.M.P.); Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Mass (A.B., D.J.C.); Clinical Trials and Evaluation Unit, Royal Brompton Hospital, London, UK (A.B.); and Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass (D.J.C.).
Correspondence to David J. Cohen, MD, MSc, Cardiovascular Division, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215. E-mail dcohen{at}caregroup.harvard.edu
Received March 31, 2003; de novo received February 2, 2004; revision received March 25, 2004; accepted March 29, 2004.
Background— Outcomes after percutaneous coronary intervention (PCI) have been documented extensively in clinical trials and single-center series, but few data exist on the clinical and economic outcomes after PCI in an unselected population.
Methods and Results— We used the Medicare Standard Analytic File to identify all initial PCI procedures performed in 1998 among a random sample of 5% of all Medicare beneficiaries 
65 years of age. These patients (n=9868) were followed up for 1 year after PCI to identify clinical outcomes, medical resource use, and costs. Between 1 month and 1 year after PCI, 16.9% of patients required 1 repeat revascularization procedures. Mean 1-year medical care costs increased 5-fold among patients with repeat revascularization compared with those without ($26 186 versus $5344; P<0.001). After adjustment for baseline differences, the independent cost of repeat revascularization was $19 074 (95% CI, 18 440 to 19 707). Assuming from previous studies that 85% of repeat revascularization procedures over the first year of follow-up are attributable to restenosis, the estimated clinical restenosis rate was 14.4%, and the 1-year economic burden of restenosis to the healthcare system was $2747 per initial PCI procedure.
Conclusions— Among unselected elderly patients undergoing PCI, repeat revascularization occurs in 
14% and increases 1-year healthcare costs by >$19 000 per occurrence. These findings have important implications for the cost-effectiveness of new treatments that substantially reduce restenosis.
Key Words: angioplasty • cost-benefit analysis • epidemiology • restenosis • stents
This article has been cited by other articles:
 |
|
 |
|
  H. V. Anderson Drug-Eluting Stents: Life Insurance With a Better Death Benefit J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2025 - 2027. [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Corbett ETHICAL ISSUES, JUSTIFICATION, REFERRAL CRITERIA FOR BUDGET LIMITED AND HIGH-DOSE PROCEDURES Radiat Prot Dosimetry, April 1, 2008; (2008) ncn089v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kuwabara, S. Matsuda, Y. Imanaka, K. Fushimi, H. Hashimoto, and K. Ishikawa The effect of age and procedure on resource use for patients with cerebrovascular disease J Health Serv Res Policy, January 1, 2008; 13(1): 26 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ryan and D. J. Cohen Are Drug-Eluting Stents Cost-Effective?: It Depends on Whom You Ask Circulation, October 17, 2006; 114(16): 1736 - 1744. [Full Text] [PDF]
|
|
|
|
|
|
A. Bakhai, G. W. Stone, E. Mahoney, T. A. Lavelle, C. Shi, R. H. Berezin, B. J. Lahue, M. A. Clark, M. J. Lacey, M. E. Russell, et al. Cost Effectiveness of Paclitaxel-Eluting Stents for Patients Undergoing Percutaneous Coronary Revascularization: Results From the TAXUS-IV Trial J. Am. Coll. Cardiol., July 18, 2006; 48(2): 253 - 261. [Abstract] [Full Text] [PDF]
|
|